Optimizing Clinical Outcomes by Optimizing the Management of Hyperlipidemia is organized by C3-Interventional Academy.

Release Date: Jan 01, 2020
Expiration Date: Feb 29, 2020

Target Audience:
This activity is designed for attendees of C3 Annual Meeting and other clinicians: interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, primary care physicians, technologists and nurses who manage thrombotic risks across diverse patient populations.

Ciné-Med designates this enduring material for a maximum of 1.5 AMA PRA Category 1Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Objectives:
Upon completion of this activity learners should be able to:
• Describe the relationship between LDL-C and cardiovascular disease as well as the substantial residual risk among patients receiving statin therapy.
• Discuss PCSK9 inhibition as a novel mechanism to reduce LDL-C and improve cardiovascular outcomes.
• Identify the impact of PCSK9 inhibitors on coronary plaque, clinical outcomes, and safety, in particular neurocognitive events.
• Describe recent ACC/AHA guidelines for the management of hyperlipidemia in the context of clinical cases.

Additional details will be posted as soon as information is available.




Diabetes Type 1: Current Approaches in Patient Management for Individuals Diagnosed with Type 1 Diabetes
Oct 06, 2022 - Jun 02, 2025 | Text-Based CME
Endocrinology, Metabolism and Diabetes
2.5 Contact Hours
More actions
Chronic Obstructive Pulmonary Disease (COPD): Patient Management
Feb 12, 2020 - May 01, 2025 | Text-Based CME
6 Contact Hours
More actions
Risk Stratification of a Pulmonary Embolism: What You Need to Know and Why
May 21, 2021 - May 21, 2024 | Text-Based CME
1.5 Contact Hours
More actions